Regeneron Pharmaceuticals, Inc.
NASDAQ:REGNBiotechnology
-$5.45 today
- Market cap
- $97.80B
- Beta
- 0.24
- P/E (TTM)
- 14.2
- EPS (TTM)
- $42.53
- Dividend yield
- 0.60%
Volume 0.70M
Average 0.91M
REGN Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Regeneron Pharmaceuticals, Inc.NASDAQ: REGN
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue grows, but more slowly than its trailing trend
Q2 FY2026 cost of revenue of $576.5M rose 8.7% year over year, behind the +14.7% change in trailing-twelve-month cost of revenue. Sequentially, it fell 13.9% from the prior quarter. Over 3 fiscal years it compounded at +7.2% a year.
Context
- Cost of revenue amounted to 14.6% of revenue in FY2025, up 0.8 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +8.7% toward the trailing-twelve-month pace of +14.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 2.1B USD
- Year-over-year change
- +6.6%
- 4-year CAGR
- -6.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.1B | +6.6% |
| FY2024 | 2024-12-31 | 1.97B | -12.2% |
| FY2023 | 2023-12-31 | 2.24B | +31.6% |
| FY2022 | 2022-12-31 | 1.71B | -37.4% |
| FY2021 | 2021-12-31 | 2.72B | — |
Cost of Revenue vs competitors
How REGN compares with its peers on the latest reported figures
- REGN's LTM Jun 2026 cost of revenue of $2.35B is the 6th highest of the 9 companies compared; the peer median is $4.71B.
- Its year-over-year change of +14.7% is the 4th highest of 8, against a peer median of +8.5%.
- Cost of revenue amounts to 15.1% of revenue for REGN, versus a peer median of 22.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $14.22B | +8.5% | +5.7% | 25.6% | |
| LTM Sep 2026 | $12.38B | +20.9% | -5.0% | 19.9% | |
| LTM Jun 2026 | $10.43B | -15.9% | +18.8% | 27.3% | |
| LTM Jun 2026 | $6.22B | +0.3% | +3.3% | 20.4% | |
| LTM Jun 2026 | $3.21B | +17.0% | +8.3% | 32.3% | |
| LTM Jun 2026 | $2.35B | +14.7% | +7.2% | 15.1% | |
| LTM Jun 2026 | $288M | — | — | 7.0% | |
| LTM Mar 2026 | $6.64M | +19.4% | +13.1% | 12.8% | |
| LTM Mar 2026 | $1.79M | -52.4% | -37.2% | 23.5% | |
| Peer median (excluding REGN) | $4.71B | +8.5% | +5.7% | 22.0% | |
Competitors are the stored peer set for REGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 16.07B | 12.17B | 13.12B | 14.2B | 14.34B |
| Cost of Revenue | 2.72B | 1.71B | 2.24B | 1.97B | 2.1B |
| Gross Profit | 13.35B | 10.47B | 10.87B | 12.23B | 12.24B |
| Gross Margin | 83.1% | 86.0% | 82.9% | 86.1% | 85.4% |
| Research & Development | 2.62B | 3.06B | 3.99B | 5.23B | 5.85B |
| Selling, General & Admin | 1.82B | 2.12B | 2.54B | 2.95B | 2.7B |
| Operating Expenses | 4.4B | 5.08B | 6.52B | 8.24B | 8.66B |
| Depreciation & Amortization | 286.2M | 341.4M | 421M | 482.9M | 543.7M |
| EBITDA | 9.67B | 5.26B | 4.69B | 5.32B | 5.82B |
| EBITDA Margin | 60.2% | 43.2% | 35.8% | 37.4% | 40.6% |
| Operating Income | 8.95B | 5.39B | 4.35B | 3.99B | 3.58B |
| Operating Margin | 55.7% | 44.2% | 33.2% | 28.1% | 24.9% |
| Interest Income | 0 | 160.1M | 495.9M | 711.4M | 716.8M |
| Interest Expense | 57.3M | 59.4M | 73M | 55.2M | 43.8M |
| Other Income / Expenses | 379M | (526.8M) | (149.3M) | 789.2M | 1.65B |
| Income Before Tax | 9.33B | 4.86B | 4.2B | 4.78B | 5.23B |
| Pre-Tax Margin | 58.0% | 39.9% | 32.0% | 33.7% | 36.5% |
| Income Tax Expense | 1.25B | 520.4M | 245.7M | 367.3M | 725.8M |
| Net Income | 8.08B | 4.34B | 3.95B | 4.41B | 4.5B |
| Net Margin | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% |
| EPS (Basic) | 76.40 | 40.51 | 37.05 | 40.90 | 43.07 |
| EPS (Diluted) | 71.97 | 38.22 | 34.77 | 38.34 | 41.48 |
| Weighted Avg Shares | 105.7M | 107.1M | 106.7M | 107.9M | 104.6M |
| Weighted Avg Shares (Diluted) | 112.2M | 113.5M | 113.7M | 115.1M | 108.6M |
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
Intrinsic Alpha fair value
Locked
Current Price
$945.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.